Background: Linperlisib is a highly selective small-molecule inhibitor of phosphatidylinositol-3-kinase delta for the treatment of relapsed/refractory follicular lymphoma.

Methods: The patient was a 64-year-old male with peripheral T-cell lymphoma and diabetes mellitus who experienced hyperglycemia, hyponatremia, facial palsy, and myalgia during linperlisib treatment. Methods: Drug-induced high blood sugar and hyponatremia. Methods: Active management of hyperglycemia during hospitalization and hyponatremia was corrected with active symptomatic treatment.

Results: During hospitalization, the patient's hyperglycemia and hyponatremia were effectively managed through active symptomatic treatment. However, following a reduction in the linperlisib dose, the patient developed recurrent hyperglycemia, hyponatremia, and new-onset myalgia. Consequently, the patient declined further linperlisib therapy and permanently discontinued the medication.

Conclusions: Clinicians should be aware of the risk of complications such as hyperglycemia and hyponatremia in patients with lymphoma and diabetes receiving linperlisib.